Pfizer

Global pharmaceutical leader Pfizer has entered a strategic partnership with Indian pharma giant Cipla to jointly market four of its major brands in India. The alliance aims to leverage Cipla’s extensive domestic distribution network and Pfizer’s internationally recognized products, enhancing reach, sales growth, and patient access. Analysts see the deal as a strategic alignment that strengthens both companies’ market positioning in India’s rapidly expanding healthcare sector.

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, expanding protection against a broader range of pneumococcal disease-causing serotypes. The introduction marks a significant advancement in preventive healthcare, offering coverage against 20 strains of Streptococcus pneumoniae, which can cause severe illnesses such as pneumonia, meningitis, and sepsis. PCV20 is designed for both pediatric and adult immunization, potentially reducing hospitalizations and associated healthcare costs.